New radiation drug shows promise for Tough-to-Treat prostate cancer
NCT ID NCT05114746
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study tested a drug called 177Lu-PSMA-617 in 94 people in Japan with a type of advanced prostate cancer that had stopped responding to hormone therapy. The drug delivers radiation directly to cancer cells. The goal was to see if it could shrink tumors and how safe it was. This is a disease control approach, not a cure, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
Kobe, Hyōgo, 6500047, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 236-0004, Japan
-
Novartis Investigative Site
Chiba, 260-8717, Japan
-
Novartis Investigative Site
Fukushima, 9601295, Japan
-
Novartis Investigative Site
Ishikawa, 9208641, Japan
-
Novartis Investigative Site
Kyoto, 6068507, Japan
Conditions
Explore the condition pages connected to this study.